血液科

订阅

MedSci主页 / 所有栏目 / 血液科

治疗血癌新希望：免疫疗法

2015-05-15 佚名 生物谷

免疫治疗方法多发性骨髓瘤血癌

本周三研究人员发表评论说，一种新型免疫治疗方法，为最常见的第三种血癌，多发性骨髓瘤患者带来了希望。名为 elotuzumab的单抗药物，由Bristol Myers-Squibb制造，去年被美国FDA指定授予突破性疗法。临床3期实验包括了646名患有多发性骨髓瘤的患者，他们是在最初接受标准治疗（lenalidomide和dexamethasone）后又复发的。患者们随机接受标准治疗或者是标准治疗外

本周三研究人员发表评论说，一种新型免疫治疗方法，为最常见的第三种血癌，多发性骨髓瘤患者带来了希望。

名为 elotuzumab的单抗药物，由Bristol Myers-Squibb制造，去年被美国FDA指定授予突破性疗法。

临床3期实验包括了646名患有多发性骨髓瘤的患者，他们是在最初接受标准治疗（lenalidomide和dexamethasone）后又复发的。

患者们随机接受标准治疗或者是标准治疗外加elotuzumab。这是一个开放性研究，即病人和医生都知道他们用了什么药物。

在接下来的2年的随诊期间，用了额外药物的患者与另外的患者相比，死亡风险或是复发风险均低30%。

那些使用了elotuzumab的小组平均生存期为19.4个月，而且他们的病情没有恶化，而标准治疗组的患者们平均生存期为14.5个月，研究人员称这种差异为显著性差异。

来自Emory大学，Winship癌症研究所的首席医疗官Sagar Lonial说， elotuzumab使用组有更长时间的肿瘤消退和更高的总体反应率，而且副作用没有升高，生活质量也没有下降。

他说，这个药物是通过在免疫系统中，同时靶向肿瘤细胞和提高自然杀伤细胞活性而发挥作用的。

"如果你愿意，可以这么理解，在许多方面，这种治疗方法对于肿瘤来说是祸不单行的。"他在一个电话会议上告诉报道者们说。

这项研究由Bristol Myers-Squibb和 AbbVie资助。有关这项研究的报道先于美国临床癌症协会会议，这个会议将在这个月晚些时候在芝加哥举行。

原始出处：


评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1969912, encodeId=d0c119699129c, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Mon Aug 03 15:25:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23876, encodeId=e667238e680, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 19:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23798, encodeId=187423e98e4, content=科学源于创新与尝试, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUNfdk68bHutYruGyxbKDzPWH3agcmId19Yf94FiapyicN0LTg0jykhqIhjPQVdR08FGR399rBpZIg/132, createdBy=feae1624323, createdName=Dr.LV, createdTime=Sun May 17 07:07:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589568, encodeId=a00d158956817, content=<a href='/topic/show?id=8b378949642' target=_blank style='color:#2F92EE;'>#血癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89496, encryptionId=8b378949642, topicName=血癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db117750430, createdName=liuhuangbo, createdTime=Sun May 17 04:25:00 CST 2015, time=2015-05-17, status=1, ipAttribution=)]
    2015-08-03 珙桐

    #新希望#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1969912, encodeId=d0c119699129c, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Mon Aug 03 15:25:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23876, encodeId=e667238e680, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 19:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23798, encodeId=187423e98e4, content=科学源于创新与尝试, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUNfdk68bHutYruGyxbKDzPWH3agcmId19Yf94FiapyicN0LTg0jykhqIhjPQVdR08FGR399rBpZIg/132, createdBy=feae1624323, createdName=Dr.LV, createdTime=Sun May 17 07:07:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589568, encodeId=a00d158956817, content=<a href='/topic/show?id=8b378949642' target=_blank style='color:#2F92EE;'>#血癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89496, encryptionId=8b378949642, topicName=血癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db117750430, createdName=liuhuangbo, createdTime=Sun May 17 04:25:00 CST 2015, time=2015-05-17, status=1, ipAttribution=)]
    2015-05-17 huaxipanxing

    看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1969912, encodeId=d0c119699129c, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Mon Aug 03 15:25:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23876, encodeId=e667238e680, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 19:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23798, encodeId=187423e98e4, content=科学源于创新与尝试, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUNfdk68bHutYruGyxbKDzPWH3agcmId19Yf94FiapyicN0LTg0jykhqIhjPQVdR08FGR399rBpZIg/132, createdBy=feae1624323, createdName=Dr.LV, createdTime=Sun May 17 07:07:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589568, encodeId=a00d158956817, content=<a href='/topic/show?id=8b378949642' target=_blank style='color:#2F92EE;'>#血癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89496, encryptionId=8b378949642, topicName=血癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db117750430, createdName=liuhuangbo, createdTime=Sun May 17 04:25:00 CST 2015, time=2015-05-17, status=1, ipAttribution=)]
    2015-05-17 Dr.LV

    科学源于创新与尝试

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1969912, encodeId=d0c119699129c, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Mon Aug 03 15:25:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23876, encodeId=e667238e680, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 19:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23798, encodeId=187423e98e4, content=科学源于创新与尝试, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUNfdk68bHutYruGyxbKDzPWH3agcmId19Yf94FiapyicN0LTg0jykhqIhjPQVdR08FGR399rBpZIg/132, createdBy=feae1624323, createdName=Dr.LV, createdTime=Sun May 17 07:07:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589568, encodeId=a00d158956817, content=<a href='/topic/show?id=8b378949642' target=_blank style='color:#2F92EE;'>#血癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89496, encryptionId=8b378949642, topicName=血癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db117750430, createdName=liuhuangbo, createdTime=Sun May 17 04:25:00 CST 2015, time=2015-05-17, status=1, ipAttribution=)]
    2015-05-17 liuhuangbo

    #血癌#

    0